Role of KLF5 in Hormonal Signaling and Breast Cancer Development

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 213-225

  Liu, Rong ^a   Dong, Jin Tang ^b   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen; Breast cancer; Estrogen; KLF5; Progesterone

Indexed keywords

EID: 84880311787     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00002-2     Document Type: Chapter

References (74)

1. Abdulkareem I.H., Zurmi I.B. Review of hormonal treatment of breast cancer. Nigerian Journal of Clinical Practice 2012, 15:9-14.
2. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 2008, 40:499-507.
3. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
4. Brinton L.A., Richesson D., Leitzmann M.F., Gierach G.L., Schatzkin A., Mouw T., et al. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiology, Biomarkers & Prevention 2008, 17:3150-3160.
5. Campbell F.C., Blamey R.W., Elston C.W., Morris A.H., Nicholson R.I., Griffiths K., et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 1981, 2:1317-1319.
6. Chanchevalap S., Nandan M.O., Merlin D., Yang V.W. All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5. FEBS Letters 2004, 578:99-105.
7. Chen F.P. Postmenopausal hormone therapy and risk of breast cancer. Chang Gung Medical Journal 2009, 32:140-147.
8. Chen C., Benjamin M.S., Sun X., Otto K.B., Guo P., Dong X.Y., et al. KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. International Journal of Cancer 2006, 118:1346-1355.
9. Chen C., Bhalala H.V., Qiao H., Dong J.T. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002, 21:6567-6572.
10. Chen C., Sun X., Guo P., Dong X.Y., Sethi P., Cheng X., et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. The Journal of Biological Chemistry 2005, 280:41553-41561.
11. Chen C., Zhou Z., Guo P., Dong J.T. Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Letters 2007, 581:1124-1130.
12. Chen C., Zhou Y., Zhou Z., Sun X., Otto K.B., Uht R.M., et al. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 2004, 330:133-142.
13. Colditz G.A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. Journal of the National Cancer Institute 1998, 90:814-823.
14. Conkright M.D., Wani M.A., Anderson K.P., Lingrel J.B. A gene encoding an intestinal-enriched member of the Kruppel-like factor family expressed in intestinal epithelial cells. Nucleic Acids Research 1999, 27:1263-1270.
15. Conneely O.M., Mulac-Jericevic B., Arnett-Mansfield R. Progesterone signaling in mammary gland development. Ernst Schering Foundation Symposium Proceedings 2007, 45-54.
16. Davis S.R., Hirschberg A.L., Wagner L.K., Lodhi I., von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. The Journal of Clinical Endocrinology and Metabolism 2009, 94:4907-4913.
17. Dimitrakakis C., Bondy C. Androgens and the breast. Breast Cancer Research 2009, 11:212.
18. Du J.X., Hagos E.G., Nandan M.O., Bialkowska A.B., Yu B., Yang V.W. The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Kruppel-like factor 5 protein. The Journal of Biological Chemistry 2011, 286:40354-40364.
19. Edwards D.P. Regulation of signal transduction pathways by estrogen and progesterone. Annual Review of Physiology 2005, 67:335-376.
20. Eliassen A.H., Hankinson S.E. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: Prospective studies. Advances in Experimental Medicine and Biology 2008, 630:148-165.
21. Forsbach G., Guitron-Cantu A., Vazquez-Lara J., Mota-Morales M., Diaz-Mendoza M.L. Virilizing adrenal adenoma and primary amenorrhea in a girl with adrenal hyperplasia. Archives of Gynecology and Obstetrics 2000, 263:134-136.
22. Fujiu K., Manabe I., Ishihara A., Oishi Y., Iwata H., Nishimura G., et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circulation Research 2005, 97:1132-1141.
23. Graham J.D., Mote P.A., Salagame U., van Dijk J.H., Balleine R.L., Huschtscha L.I., et al. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009, 150:3318-3326.
24. Guo P., Dong X.Y., Zhang X., Zhao K.W., Sun X., Li Q., et al. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. The Journal of Biological Chemistry 2009, 284:6071-6078.
25. Guo P., Dong X.Y., Zhao K.W., Sun X., Li Q., Dong J.T. Opposing effects of KLF5 on the transcription of Myc in epithelial proliferation in the context of TGFbeta. The Journal of Biological Chemistry 2009, 284:28243-28252.
26. Guo P., Dong X.Y., Zhao K.W., Sun X., Li Q., Dong J.T. Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells. International Journal of Cancer 2010, 126:81-89.
27. Guo P., Zhao K.W., Dong X.Y., Sun X., Dong J.T. Acetylation of KLF5 alters the assembly of P15 transcription factors in TGFbeta-mediated induction in epithelial cells. The Journal of Biological Chemistry 2009, 284:18184-18193.
28. Hankinson S.E., Colditz G.A., Willett W.C. Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Research 2004, 6:213-218.
29. Haslam S. Role of progesterone in the etiology of breast cancer in an animal model 2010, 146.
30. Hissom J.R., Moore M.R. Progestin effects on growth in the human breast cancer cell line T-47D-Possible therapeutic implications. Biochemical and Biophysical Research Communications 1987, 145:706-711.
31. Horwitz K.B., Dye W.W., Harrell J.C., Kabos P., Sartorius C.A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5774-5779.
32. Hu R., Dawood S., Holmes M.D., Collins L.C., Schnitt S.J., Cole K., et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clinical Cancer Research 2011, 17:1867-1874.
33. Ismail P.M., Amato P., Soyal S.M., DeMayo F.J., Conneely O.M., O'Malley B.W., et al. Progesterone involvement in breast development and tumorigenesis-As revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 2003, 68:779-787.
34. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: Twenty-eight years later. Journal of Clinical Oncology 1995, 13:513-529.
35. Jensen E.V., Jordan V.C. The estrogen receptor: A model for molecular medicine. Clinical Cancer Research 2003, 9:1980-1989.
36. Jiang J., Chan Y.S., Loh Y.H., Cai J., Tong G.Q., Lim C.A., et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nature Cell Biology 2008, 10:353-360.
37. Johnston S.R., Dowsett M. Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nature Reviews. Cancer 2003, 3:821-831.
38. Joshi P.A., Jackson H.W., Beristain A.G., Di Grappa M.A., Mote P.A., Clarke C.L., et al. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
39. Kabos P., Haughian J.M., Wang X., Dye W.W., Finlayson C., Elias A., et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Research and Treatment 2011, 128:45-55.
40. Kenemans P., van der Mooren M.J. Androgens and breast cancer risk. Gynecological Endocrinology 2012, 28(Suppl. 1):46-49.
41. Kirsh V., Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes & Control 2002, 13:583-590.
42. Lanari C., Lamb C.A., Fabris V.T., Helguero L.A., Soldati R., Bottino M.C., et al. The MPA mouse breast cancer model: Evidence for a role of progesterone receptors in breast cancer. Endocrine-Related Cancer 2009, 16:333-350.
43. Lange C.A. Challenges to defining a role for progesterone in breast cancer. Steroids 2008, 73:914-921.
44. Lee M.Y., Moon J.S., Park S.W., Koh Y.K., Ahn Y.H., Kim K.S. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells. The Biochemical Journal 2009, 417:313-322.
45. Liang Y., Besch-Williford C., Brekken R.A., Hyder S.M. Progestin-dependent progression of human breast tumor xenografts: A novel model for evaluating antitumor therapeutics. Cancer Research 2007, 67:9929-9936.
46. Lippman M.E., Allegra J.C. Quantitative estrogen receptor analyses: The response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 1980, 46:2829-2834.
47. Liu R., Zheng H.Q., Zhou Z., Dong J.T., Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. The Journal of Biological Chemistry 2009, 284:16791-16798.
48. Liu R., Zhou Z., Zhao D., Chen C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Molecular Endocrinology 2011, 25:1137-1144.
49. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery C.A., et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes & Development 1995, 9:2266-2278.
50. McConnell B.B., Kim S.S., Yu K., Ghaleb A.M., Takeda N., Manabe I., et al. Kruppel-like factor 5 is important for maintenance of crypt architecture and barrier function in mouse intestine. Gastroenterology 2011, 141(1302-1313):e1306.
51. Nakajima Y., Akaogi K., Suzuki T., Osakabe A., Yamaguchi C., Sunahara N., et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5. Science Signaling 2011, 4:ra22.
52. Nandan M.O., McConnell B.B., Ghaleb A.M., Bialkowska A.B., Sheng H., Shao J., et al. Kruppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis. Gastroenterology 2008, 134:120-130.
53. Ni M., Chen Y., Lim E., Wimberly H., Bailey S.T., Imai Y., et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011, 20:119-131.
54. Oishi Y., Manabe I., Tobe K., Tsushima K., Shindo T., Fujiu K., et al. Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metabolism 2005, 1:27-39.
55. Parisi S., Passaro F., Aloia L., Manabe I., Nagai R., Pastore L., et al. Klf5 is involved in self-renewal of mouse embryonic stem cells. Journal of Cell Science 2008, 121:2629-2634.
56. Rana A., Rangasamy V., Mishra R. How estrogen fuels breast cancer. Future Oncology 2010, 6:1369-1371.
57. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 2004, 11:643-658.
58. Sartorius C.A., Harvell D.M., Shen T., Horwitz K.B. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Research 2005, 65:9779-9788.
59. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA: The Journal of the American Medical Association 2000, 284:691-694.
60. Secreto G., Venturelli E., Meneghini E., Greco M., Ferraris C., Gion M., et al. Testosterone and biological characteristics of breast cancers in postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 2009, 18:2942-2948.
61. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
62. Takagi K., Miki Y., Onodera Y., Nakamura Y., Ishida T., Watanabe M., et al. Kruppel-like factor 5 in human breast carcinoma: A potent prognostic factor induced by androgens. Endocrine-Related Cancer 2012, 19:741-750.
63. Thiantanawat A., Long B.J., Brodie A.M. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Research 2003, 63:8037-8050.
64. Tong D., Czerwenka K., Heinze G., Ryffel M., Schuster E., Witt A., et al. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clinical Cancer Research 2006, 12:2442-2448.
65. Traish A.M., Feeley R.J., Guay A.T. Testosterone therapy in women with gynecological and sexual disorders: A triumph of clinical endocrinology from 1938 to 2008. The Journal of Sexual Medicine 2009, 6:334-351.
66. van Staa T.P., Sprafka J.M. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009, 62:76-80.
67. Wan H., Luo F., Wert S.E., Zhang L., Xu Y., Ikegami M., et al. Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development 2008, 135:2563-2572.
68. Zhao Y., Hamza M.S., Leong H.S., Lim C.B., Pan Y.F., Cheung E., et al. Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells. Oncogene 2008, 27:1-8.
69. Zhao K.W., Sikriwal D., Dong X., Guo P., Sun X., Dong J.T. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. The Biochemical Journal 2011, 437:323-333.
70. Zhao D., Zheng H.Q., Zhou Z., Chen C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Research 2010, 70:4728-4738.
71. Zhao D., Zhi X., Zhou Z., Chen C. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 2012, 33:59-67.
72. Zheng H.Q., Zhou Z., Huang J., Chaudhury L., Dong J.T., Chen C. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene 2009, 28:3702-3713.
73. Zhi X., Zhao D., Zhou Z., Liu R., Chen C. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. The American Journal of Pathology 2012, 180:2452-2461.
74. Zhu N., Gu L., Findley H.W., Chen C., Dong J.T., Yang L., et al. KLF5 interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. The Journal of Biological Chemistry 2006, 281:14711-14718.